NCT06787586 - Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Normal VolunteersAtopic Dermatitis (AD)Atopic EczemaChronic Pruritus

Interventions

DRUG

ATTO-1310

ATTO-1310 Attobody

DRUG

ATTO-1310 Placebo

Placebo preparation to match ATTO-1310 Dose

Trial Locations (14)

33134

RECRUITING

Attovia Clinical Site 109, Coral Gables

46168

RECRUITING

Attovia Clinical Site 102, Plainfield

64506

RECRUITING

Attovia Clinical Site 104, Saint Joseph

78213

RECRUITING

Attovia Clinical Site 108, San Antonio

89509

RECRUITING

Attovia Clinical Site 106, Reno

92024

RECRUITING

Attovia Clinical Site 103, Encinitas

95765

RECRUITING

Attovia Clinical Site 116, Rocklin

95815

RECRUITING

Attovia Clinical Site 107, Sacramento

E3B1G9

RECRUITING

Attovia Clinical Site 110, Fredericton

L3Y 5G8

RECRUITING

Attovia Clinical Site 111, Newmarket

K9J 5K2

RECRUITING

Attovia Clinical Site 112, Peterborough

M4W 2N4

RECRUITING

Attovia Clinical Site 113, Toronto

H2X2V1

RECRUITING

Attovia Clinical Site 105, Montreal

H3P 3P1

ACTIVE_NOT_RECRUITING

Altasciences, Montreal